Cell line · CVCL_0445
Papers64
1 to 20 of 64
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Out-of-frame CBX3::ALK fusion drives ALK activation and therapy response. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Thrombomodulin facilitates melanoma progression via FAK- and ezrin-mediated phenotypic plasticity. | J Biomed Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tissue-dependent mechanosensing by cells derived from human tumors. | NPJ Biol Phys Mech | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| RAC1-Amplified and RAC1-A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept Study. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SIAH3 is frequently epigenetically silenced in cancer and regulates mitochondrial metabolism. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagy-dependent melanoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function. | Genes (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma. | Mol Immunol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0445/papers